NCEL
NewcelX Ltd. NASDAQ$3.78
Mkt Cap $1.7M
52w Low $1.83
6.7% of range
52w High $30.80
50d MA $2.80
200d MA $9.36
P/E (TTM)
-0.1x
EV/EBITDA
0.0x
P/B
0.2x
Debt/Equity
0.0x
ROE
-114.5%
P/FCF
-0.4x
RSI (14)
—
ATR (14)
—
Beta
0.57
50d MA
$2.80
200d MA
$9.36
Avg Volume
42.6K
About
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 4, 2025 | AMC | — | -5.54 | — | — | — | — | — | — | — | — | — |
| May 15, 2024 | AMC | -8.40 | -0.00 | +100.0% | 58.40 | -6.5% | +2.4% | +12.3% | +21.2% | +4.8% | +9.6% | — |
| Jun 30, 2023 | AMC | -6.80 | -0.20 | +97.1% | 440.00 | +13.6% | +9.1% | +29.1% | +8.2% | -11.8% | -16.6% | — |
| May 5, 2023 | AMC | -12.00 | -0.29 | +97.5% | 552.00 | -2.2% | -2.9% | -9.4% | -8.0% | -11.6% | -24.6% | — |
| Oct 11, 2022 | AMC | — | -0.54 | — | 190.00 | -2.3% | +1.1% | +0.0% | +9.5% | +10.3% | +5.3% | — |
| Mar 24, 2022 | AMC | -13.80 | -0.50 | +96.4% | 576.10 | -2.8% | -1.4% | -7.7% | -6.3% | -5.6% | -2.1% | — |
| Sep 28, 2021 | AMC | — | -0.42 | — | 988.00 | -0.8% | +2.0% | +1.2% | +0.8% | +0.4% | +0.4% | — |
| May 14, 2021 | AMC | -6.80 | -0.34 | +95.0% | 1344.00 | -0.3% | +0.3% | +2.7% | +4.8% | +3.9% | +2.7% | — |
Data updated apr 26, 2026 2:25pm
· Source: massive.com